IL-6 blockade

研究成果: Review article査読

1 被引用数 (Scopus)

抄録

Interleukin-6 (IL-6) plays an important role in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab, anti-human IL-6 receptor monoclonal antibody developed in Japan, prevents IL-6 from binding to IL-6 receptor blocking IL-6 signal. The clinical and radiographic efficacy of tocilizumab has proved in many clinical studies. Tocilizumab monotherapy is superior to methotrexate, which has not proved in TNF inhibitors, although tocilizuab in combination with methotrexate is more effective than tocilizumab monotherapy in inducing remission. Hepatotoxicity and infection are adverse events to be careful about.

本文言語English
ページ(範囲)963-967
ページ数5
ジャーナルNihon rinsho. Japanese journal of clinical medicine
74
6
出版ステータスPublished - 2016 6 1

ASJC Scopus subject areas

  • Medicine(all)

フィンガープリント 「IL-6 blockade」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル